Drugs / CD19-CD22 CAR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04034446 | Sep 2019 → Jul 2020 | B-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04714593 | Jan → Dec 2021 | B-cell acute lymphoblastic leukemia | Shanxi Province Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04715217 | Jan 2021 → Oct 2024 | B-cell non-Hodgkin lymphoma | Shanxi Province Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CD22 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04034446 ↗ |
| Modality | Cell therapy | “CD19-CD22 CAR-T cells” NCT04034446 ↗ |
| Route | Intravenous | “will be intravenously infuse with 0.5×10\^6 CAR+T cells/kg.” NCT04714593 ↗ |
| Target | CD19 | “CD19-CD22 CAR-T cells” NCT04034446 ↗ |
| Target | CD22 | “CD19-CD22 CAR-T cells” NCT04034446 ↗ |